Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Pavlotsky, Abraham; Eidelman, A.; Barak, Frida; Alon, Haim; Horn, Y.

doi:10.1002/jso.2930410106

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The selection of drugs currently used for IVC is based on the results observed in clinical trials and series and the lack of toxicity and availability of the drug [ 121. Randomized trials have shown a reduction in recurrence rates in patients receiving adjuvant intravesical pharmacotherapy with BCG [I], doxorubicin [5], mitomycin C [8], or thiotepa [ 131. The drugs most frequently used for IVC are thiotepa, BCG, and MMC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term follow‐up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C

Pavlotsky

Eidelman

Barak

et al. 1995

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Prophylactic intravesical chemotherapy (IVC) reduces recurrence rates of superficial transitional cell carcinoma (TCC) of the urinary bladder. The patient cohort existed of 86 individuals (stage TaN0M0 or T1N0M0) superficial carcinoma of various grades of malignancy. Following initial transuretheral resection or diagnostic cystoscopy, mitomycin C (MMC), 20 mg dissolved in 50 ml saline, was instilled intravesically by catheter over 1 hr at 2-week intervals, initially and then four more times followed by diagnostic cystoscopy (one course = 12 weeks). Two similar courses were administered thereafter for a total period of 36 weeks. For patients in remission, installations continued in monthly fractionations for 9 more months (cystoscopy every 3 months) and then at 2-month intervals for 12 more months (cystoscopy every 6 months). When cystoscopy revealed recurrence, IVC was repeated from the beginning. No symptoms of MMC-related toxicity were observed. Cystoscopic follow-up evaluations showed a complete response rate of 84% at 3 years and 81% at 5 years after initial therapy. Twenty-seven patients who had not responded to previous treatment with other drugs responded to MMC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In previous work [8], we summarized our preliminary experience with intravesical MMC administered for a period of 36 weeks. We now report our extended experience to include a 5-year period of follow-up review and treatment of a larger number of patients according to the same protocol.…”

Section: Introductionmentioning

confidence: 99%